Immune signatures may predict adverse events from immunotherapy

Distinct immune “signatures” in patients who develop adverse events while receiving immunotherapy for cancer may help oncologists identify patients at risk and treat them early to prevent serious side effects, suggests a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup